Lybalvi Now Available for Schizophrenia, Bipolar I Disorder
Lybalvi is an atypical antipsychotic comprised of samidorphan co-formulated with olanzapine in a single bilayer tablet.
General Psychiatry
Invega Hafyera Approved for Twice-Yearly Treatment of Schizophrenia
The Food and Drug Administration has approved Invega Hafyera™ (paliperidone palmitate), an every 6-month injection, for the treatment of schizophrenia in adults. Invega Hafyera is a long-acting atypical antipsychotic that is administered as a gluteal intramuscular injection by a health care professional. Prior to initiating treatment with Invega Hafyera, patients must have been adequately treated…
Transcranial Magnetic Stimulation Device Cleared for Anxious Depression
The outpatient procedure provides noninvasive magnetic stimulation through a cushioned helmet to targeted areas of the brain.
Cognitive Behavioral Therapy for Insomnia in Veterans With Alcohol Use Disorder
A team of researchers plans to test the feasibility and acceptability of cognitive behavioral therapy for veterans with insomnia and alcohol use disorder.
Exploring the Connection Between Posttraumatic Stress Disorder and Cardiovascular Disease
A review by Ebrahimi and colleagues, and an interview with Beth Cohen, MD, highlights the possible mechanisms driving the association between posttraumatic stress disorder and cardiovascular disease, and the need for screening and treatment options for these patients.
Study Shows Loneliness Tied to Use of High-Risk Medications
The study authors utilized the National Social Life, Health, and Aging Project leave-behind questionnaire to obtain data on a total of 6017 adults over 65 years of age.
Important Clozapine REMS Program Changes Announced
According to the FDA, prescribers and pharmacies must be re-certified in the Clozapine REMS program by November 15, 2021 to continue to prescribe or dispense clozapine.
Prescription Digital Therapeutic for Anxiety, Depression Treatment Launched
Ensemble is an AI-powered digital mental health coach app designed to address the symptoms of MDD or GAD.
Azstarys, a Novel ADHD Treatment, Now Available
Azstarys consists of serdexmethylphenidate, a prodrug of dexmethylphenidate, co-formulated with immediate-release dexmethylphenidate.
Alcohol Withdrawal: Individualized Care and Pharmacologic Treatment
More than 50% of patients with alcohol use disorder develop alcohol withdrawal symptoms within hours of discontinuing or decreasing alcohol use.
- Loading...
Loading...
Next post in News
Loading... 
Loading...